반응식
[NH2:1][CH2:2][C:3]1[CH:4]=[C:5]2[C:10](=[CH:11][CH:12]=1)[CH2:9][CH:8]([NH:13][C:14]([C:16]1[CH:21]=[CH:20][C:19]([C:22]3[CH:27]=[CH:26][C:25]([F:28])=[CH:24][CH:23]=3)=[CH:18][CH:17]=1)=[O:15])[CH2:7][CH2:6]2.Br[C:30](Br)([CH2:33][CH3:34])[CH2:31][CH3:32].C([O-])([O-])=O.[K+].[K+]>CN(C=O)C>[N:1]1([CH2:2][C:3]2[CH:4]=[C:5]3[C:10](=[CH:11][CH:12]=2)[CH2:9][CH:8]([NH:13][C:14]([C:16]2[CH:21]=[CH:20][C:19]([C:22]4[CH:23]=[CH:24][C:25]([F:28])=[CH:26][CH:27]=4)=[CH:18][CH:17]=2)=[O:15])[CH2:7][CH2:6]3)[CH2:34][CH2:33][CH2:30][CH2:31][CH2:32]1참가 물질
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
A mixture of 4′-fluoro-biphenyl-4-carboxylic acid (6-aminomethyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-amide, 4, (0.054 g, 0.14), dibromopentane (0.022 mL, 0.16 mmol) and K2CO3 (0.099 g, 0.72 mmol) in DMF (2 mL) is stirred at room temperature for 18 hours. The reaction solution is filtered and the filtrate concentrated in vacuo to leave a crude residue which is purified by reversed prep-HPLC using CH3CN—H2O (0.1% TFA) to afforded 36 mg (57% yield) of the desired product as a foaming solid. 1H NMR (300 MHz, CD3OD) δ 7.94 (d, J=8.4 Hz, 2H), 7.72 (m, 4H), 7.25 (t, J=9.6 Hz, 5H), 4.33 (m, 1H), 4.24 (s, 2H), 3.44-3.56 (m, 3H), 3.16-3.24 (br, 1H), 2.84-3.07 (m, 4H), 2.20-2.35 (br, 1H), 1.67-2.02 (m, 6H), 1.54 (m, H1); 13C NMR (75 MHz, CD3OD) δ 168.4, 164.8, 143.4, 137.4, 137.0, 130.9, 131.5, 130.0, 128.9, 128.8, 128.5, 127.9, 126.8, 115.8, 115.5, 60.5, 52.7, 46.6, 35.0, 28.9, 28.3, 22.9, 21.6; 19F NMR (282 MHz, CD3OD) δ 46.3; LRMS: 443.6 (M+H); HRMS: calcd for C29H32FN2O: 443.2499 (M+H), found: 443.2506.
후처리
- filtrationThe reaction solution is filtered
- concentrationthe filtrate concentrated in vacuo
- customto leave a crude residue which
- customis purified by reversed
출처 및 근거
- ORD 기록
- ord-6f1b5f7ab23149a7abdb256e821d2de9
- 출처 데이터셋
- uspto-grants-2007_12
- 특허 번호
- US07304065B2
연결된 노트
불러오는 중…